Ypsomed Holding AG (YPSN)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 22 Oct 2026
Key indicators
| Last close | CHF 387.40 |
|---|---|
| 52-week range | 260.50 – 418.00 |
| Return, 1 month / 3 months | +8.2% / +1.0% |
| Return, 1 year / 3 years | +24.9% / +59.4% |
| Trend | Uptrend |
| RSI (14) | 64 |
| Volatility (1 year) | 29.4% |
| Worst drawdown (1 year) | -23.6% |
| Average daily value traded | 5.56M CHF |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ypsomed Holding AG is a Swiss medical technology company based in Burgdorf that develops and manufactures self-injection and infusion systems. It makes pen injectors, autoinjectors and insulin pumps, and supplies pharmaceutical companies that use its devices for their own medicines, as well as patients who manage conditions such as diabetes at home. The company also provides related services that support the use of its injection and infusion products.
Ypsomed Holding AG trades under the code YPSN on the SIX Swiss Exchange in Switzerland, with its price quoted in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ypsomed Holding AG (YPSN) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 387.40 on 22 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 51 of 225 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 24.9% and over the last three months it rose 1.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.8% | ||
| From 52-week high | -6.3% | ||
| Momentum | 70 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 1.0% | ||
| 6-month return | 37.2% | ||
| 12-month return, skipping the last month | 15.4% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.6% | ||
| Liquidity | 71 · Strong | Trades actively. | |
| Average daily value traded | 5.56M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 35 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.4% |
|---|---|
| 1 month | +8.2% |
| 3 months | +1.0% |
| 6 months | +37.2% |
| 1 year | +24.9% |
| 3 years | +59.4% |
| 5 years | +163.9% |
Signals
| 50-day / 200-day average | 378.45 / 334.63 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.01 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jul 2026 | CHF 4.4000 |
| 4 Jul 2025 | CHF 2.2000 |
| 1 Jul 2024 | CHF 2.0000 |
| 3 Jul 2023 | CHF 1.3000 |
| 30 Jun 2023 | CHF 0.6500 |
| 4 Jul 2022 | CHF 0.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.